Anna Koroleva leads the Life Sciences & Bioinformatics division of Medical Science & Computing, a Dovel Technologies company. With more than 15 years of leadership in building successful teams to support and deliver on customer missions, she brings deep expertise in the federal health and life sciences industry.
Koroleva joined the leadership team of MSC in 2010 and played an integral role during and following Dovel’s acquisition of MSC in 2016. In 2019, she oversaw more than $80 million in annual revenue supporting some of the National Institutes of Health’s largest institutes and centers including mission-critical programs within National Institute of Allergy and Infectious Diseases, National Library of Medicine, National Cancer Institute and the Clinical Center. She manages a team of more than 400 personnel, many of whom are frequent recipients of NIH director and NIAID merit awards.
In the last year, under Koroleva’s leadership, Dovel’s Life Science’s business unit has been involved in initiatives that kept NIAID at the forefront of today’s rapid scientific pace. Her team has led 3D visualization and printing, augmented and virtual reality, and data analysis in the cloud-computing environment for NIH.
And MSC, a longtime partner to NIH and now as a Dovel company, continues to grow and expand capabilities. Koroleva has been instrumental in leading these efforts as she has developed strong relationships with NIH stakeholders and has worked to build teams who constantly put the mission first.
Plus, Dovel’s Life Sciences business unit is at the forefront of developing state-of-the-art tools and methods, and Koroleva is leading the charge in working with emerging technologies. For example, virtual and augmented reality to enhance diagnosis, treatment, and wellness; precision medicine, an emerging approach for disease treatment and prevention; image processing and biomedical analysis; and ongoing developments in cell and gene therapy.
Together, Dovel and MSC remain steadfastly focused on supporting and advancing customers’ missions. Koroleva is focused on expanding the company’s work with regulatory affairs; scientific research; data analytics, statistical, and bioinformatic analysis; and chemical, biological, and radiological threat response.
In support of this expansion, she continues to build a robust team of highly qualified medical experts, clinical researchers and data scientists. She is always looking to provide professional development opportunities through training, certifications and challenging programs. By focusing on the expansion of new business and team development, Koroleva is propelling Dovel’s three pillars of focus — innovation, customer success and employee growth.